DE69836139T2 - Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon - Google Patents

Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon Download PDF

Info

Publication number
DE69836139T2
DE69836139T2 DE69836139T DE69836139T DE69836139T2 DE 69836139 T2 DE69836139 T2 DE 69836139T2 DE 69836139 T DE69836139 T DE 69836139T DE 69836139 T DE69836139 T DE 69836139T DE 69836139 T2 DE69836139 T2 DE 69836139T2
Authority
DE
Germany
Prior art keywords
cells
use according
gene
cell
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69836139T
Other languages
German (de)
English (en)
Other versions
DE69836139D1 (de
Inventor
J. Gary Washington NABEL
G. Elizabeth Washington NABEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Publication of DE69836139D1 publication Critical patent/DE69836139D1/de
Application granted granted Critical
Publication of DE69836139T2 publication Critical patent/DE69836139T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE69836139T 1997-07-21 1998-07-21 Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon Expired - Fee Related DE69836139T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/897,333 US6177272B1 (en) 1997-07-21 1997-07-21 Method for treating vascular proliferative diseases with p27 and fusions thereof
US897333 1997-07-21
PCT/US1998/015025 WO1999003508A2 (en) 1997-07-21 1998-07-21 METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF

Publications (2)

Publication Number Publication Date
DE69836139D1 DE69836139D1 (de) 2006-11-23
DE69836139T2 true DE69836139T2 (de) 2007-08-16

Family

ID=25407780

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69836139T Expired - Fee Related DE69836139T2 (de) 1997-07-21 1998-07-21 Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon

Country Status (8)

Country Link
US (2) US6177272B1 (enExample)
EP (1) EP0998307B1 (enExample)
JP (1) JP2001510028A (enExample)
AT (1) ATE342067T1 (enExample)
AU (1) AU8502198A (enExample)
CA (1) CA2295199C (enExample)
DE (1) DE69836139T2 (enExample)
WO (1) WO1999003508A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6413943B1 (en) * 1999-03-01 2002-07-02 Cell Genesys, Inc. Methods and reagents for inhibiting proliferation of smooth muscle cells
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
CA2362995A1 (en) 1999-03-01 2000-09-08 Cell Genesys, Inc. Anti-neoplastic compositions and uses thereof
WO2001021793A1 (fr) 1999-09-22 2001-03-29 Nobuyuki Miyasaka TRAITEMENTS CONTRE LES RHUMATISMES A BASE DE p21?Cip1¿
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) * 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US20040243097A1 (en) * 2000-05-12 2004-12-02 Robert Falotico Antiproliferative drug and delivery device
WO2002026139A1 (en) * 2000-09-29 2002-04-04 Cordis Corporation Coated medical devices
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
US20020098998A1 (en) * 2001-01-22 2002-07-25 Marks Andrew R. P27 prevents cellular migration
US20030013638A1 (en) * 2001-01-22 2003-01-16 Marks Andrew R. P27 prevents cellular migration
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US7108701B2 (en) * 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
US20030065345A1 (en) * 2001-09-28 2003-04-03 Kevin Weadock Anastomosis devices and methods for treating anastomotic sites
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
WO2006031210A1 (en) * 2003-05-29 2006-03-23 Board Of Regents, The University Of Texas Systems Jabi as a prognostic marker and a therapeutic target for human cancer
US7833339B2 (en) 2006-04-18 2010-11-16 Franklin Industrial Minerals Mineral filler composition
JP2011512408A (ja) * 2008-02-19 2011-04-21 セラドン・コーポレーション 心筋層へのウイルスベクターの取り込みを増大させるための組成物
WO2021005009A1 (en) 2019-07-05 2021-01-14 Iomx Therapeutics Ag Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
US20240010720A1 (en) 2020-07-06 2024-01-11 Iomx Therapeutics Ag Antibodies binding igv of igsf11 (vsig3) and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6242575B1 (en) 1994-01-07 2001-06-05 Fred Hutchinson Institute For Cancer Research Antibodies for detecting p27 protein
US6316208B1 (en) 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
US6355774B1 (en) 1994-01-07 2002-03-12 Fred Hutchinson Cancer Research Center Isolated p27 protein
US5688665A (en) 1994-01-07 1997-11-18 Fred Hutchinson Cancer Research Center Isolated nucleic acid molecules encoding the p27 KIP-1 protein
AU2770695A (en) 1994-07-15 1996-02-16 Fred Hutchinson Cancer Research Center Isolated p27 protein and methods for its production and use
AU5297496A (en) * 1995-02-17 1996-09-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of preparation and use of recombinant adenoviral vectors
US5962424A (en) * 1995-02-21 1999-10-05 Arch Development Corporation Methods and compositions for targeting selectins
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US6541197B2 (en) * 1996-01-22 2003-04-01 Human Gene Therapy Research Institute Vehicles for stable transfer of green fluorescent protein gene and methods of use for same
US5672508A (en) * 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
WO1998021350A1 (en) * 1996-11-13 1998-05-22 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement

Also Published As

Publication number Publication date
DE69836139D1 (de) 2006-11-23
US6884431B1 (en) 2005-04-26
WO1999003508A9 (en) 1999-05-14
EP0998307A2 (en) 2000-05-10
WO1999003508A3 (en) 1999-04-08
CA2295199C (en) 2007-07-03
AU8502198A (en) 1999-02-10
JP2001510028A (ja) 2001-07-31
ATE342067T1 (de) 2006-11-15
WO1999003508A2 (en) 1999-01-28
EP0998307B1 (en) 2006-10-11
US6177272B1 (en) 2001-01-23
CA2295199A1 (en) 1999-01-28

Similar Documents

Publication Publication Date Title
DE69836139T2 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
DE69428130T2 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
US5863904A (en) Methods for treating cancers and restenosis with P21
DE69132047T2 (de) Gentherapie gegen krankheiten die die zellteilung betreffen
DE69733605T2 (de) In vivo gentransfermethoden zur wundheilung
DE69333886T2 (de) Adenovirus-gelenkter Gen-Transfer zum Herz-und glattem vaskulären Muskel
DE69535467T2 (de) Faktor aus pigmentiertem Epithel (PEDF): Charakterisierung, genomische Organisation und Sequenz des PEDF-Gens
DE69829857T2 (de) Hypoxie-regulierte gene
DE69725882T2 (de) Adenovirus e4 proteine für induktion von zelltod
DE69432856T2 (de) Zufuhr von genprodukten mittels mesangium-zellen
DE69434997T2 (de) Menschliches Chondromodulin-I-Protein
DE60036551T2 (de) VERWENDUNG VON BAKTERIELLEN ParD kis/ParD kid TOXIN-ANTITOXIN SYSTEM ZUR TÖTUNG VON EUKARYOTISCHEN ZELLEN
DE69831231T2 (de) Modulatoren von intrazellulären entzündungs-, zelltod- und zellüberlebenswegen, die card- und kinase-domänen enthalten
DE69901805T2 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin
DE69732246T2 (de) Gewebespezifische expression des retinoblastoma-proteins
DE69935862T2 (de) Guanylat-bindendes protein (gbp-1) als inhibitor der zellproliferation
DE69929718T2 (de) Neues regulationssystem zur kontrolle der expression eines transgens
EP1059931B1 (de) Verwendung von cd137 zur förderung der proliferation peripherer monocyten
DE19957689A1 (de) Proteaseresistenter Tumorsuppressor p14(ARF)
DE60034874T2 (de) Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung
EP1097234B1 (de) Verfahren zur verbesserung des gentransfers von genetischem material in säugerzellen durch die verwendung von p21 (waf-1)
EP0840794B1 (de) Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen
US7087582B1 (en) Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
DE60116140T2 (de) Zipper proteinkinase und deren verwendungen
EP1440085A2 (de) Transiente immortalisierung von zellen durch onkogenproteine oder telomerproteine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee